Clin Psychopharmacol Neurosci.
2017 Aug;15(3):199-209. 10.9758/cpn.2017.15.3.199.
Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
- Affiliations
-
- 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- 2Department of Psychiatry, Konkuk University School of Medicine, Chungju, Korea.
- 3Department of Psychiatry, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
- 4Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
- 5Department of Psychiatry, Inje University Seoul Paik Hospital, Inje University School of Medicine, Seoul, Korea.
- 6Stress Research Institute, Inje University, Seoul, Korea.
- 7Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 8Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
- 9Paik Institute for Clinical Research, Inje University, Busan, Korea.
- 10Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
- 11Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
- 12Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea.
- KMID: 2388265
- DOI: http://doi.org/10.9758/cpn.2017.15.3.199
Abstract
- In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
- Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines
- The Development of Korean Medication Algorithm for Major Psychiatric Disorder
- The Consideration for Revision of the Korean Medication Algorithm for Schizophrenia
- Korean Medication Algorithm for Bipolar Disorder(V): Comparisons with Other Treatment Guidelines
